Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 7, 2026 | -$0.16 | -$0.12 | Beat |
| May 8, 2026 | -$0.30 | -$0.28 | Beat |
| Apr 3, 2026 | -$0.27 | $0.32 | Beat |
| Nov 7, 2025 | -$0.63 | -$0.58 | Beat |
| Aug 14, 2025 | -$0.79 | -$0.82 | Miss |
| May 9, 2025 | -$0.67 | -$1.06 | Miss |